As fall approaches, so does respiratory syncytial virus or RSV season. This year, there are more options for those most susceptible to RSV, including a new vaccine and updated RSV vaccine guidance for ...

Though there are now respiratory syncytial virus (RSV) vaccines approved by the FDA and recommended by the CDC for certain high-risk adults, what happens when someone ends up with severe illness from ...

New year, new sickness? No, not quite. While there is a whole host of viruses going around, there are thankfully no new viruses to fret about − the ones we have are bad enough. Before 2024 closed out, ...

Far fewer babies went to the hospital struggling to breathe from RSV, a severe respiratory infection, after the debut of a new vaccine and treatment this season, according to an analysis published ...

After a particularly bad stretch of the viral infection RSV in the fall of 2024, doctors say they are now treating an increasing number of influenza cases. “Not necessarily on the amount of people, ...

In a recent final analysis of a phase 3 trial, the bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccine maintained high efficacy and a favorable safety profile against RSV-associated ...

The complex shape of respiratory syncytial virus is one hurdle limiting the development of treatments for an infection that leads to hospitalization or worse for hundreds of thousands of people in the ...

The FDA approved clesrovimab (Enflonsia) to prevent lower respiratory tract disease from respiratory syncytial virus (RSV) in infants born during or entering their first RSV season, drugmaker Merck ...

The winter respiratory virus season is still in full swing, with Illinois under a "high" alert level from the Centers for Disease Control and Prevention. Among the viruses circulating most are ...

The United States is fighting a "quad-demic" this winter with four major viruses—COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus—with infants at particular risk, Dr. Ryan Fulton ...

GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% effective in preventing severe illness three years after patients 60 and older ...